Edition:
India

Madrigal Pharmaceuticals Inc (MDGL.OQ)

MDGL.OQ on NASDAQ Stock Exchange Capital Market

287.05USD
20 Jul 2018
Change (% chg)

$-1.67 (-0.58%)
Prev Close
$288.72
Open
$292.13
Day's High
$292.14
Day's Low
$283.32
Volume
55,884
Avg. Vol
120,628
52-wk High
$325.58
52-wk Low
$15.21

Chart for

About

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product,... (more)

Overall

Beta: 0.82
Market Cap(Mil.): $586.42
Shares Outstanding(Mil.): 12.50
Dividend: --
Yield (%): --

Financials

Deals of the day-Mergers and acquisitions

June 13 The following bids, mergers, acquisitions and disposals were reported by 2020 GMT on Wednesday:

14 Jun 2018

Madrigal Pharma explores sale - Bloomberg

June 13 Madrigal Pharmaceuticals Inc is exploring a sale, Bloomberg reported https://www.bloomberg.com/news/articles/2018-06-13/madrigal-pharma-is-said-to-explore-sale-amid-takeover-interest on Wednesday, citing people familiar with the matter, nearly three weeks after the company reported mid-stage data from its drug to treat non-alcoholic steatohepatitis or NASH.

13 Jun 2018

Madrigal Pharma more than doubles after liver drug study success

Madrigal Pharmaceuticals Inc's shares more than doubled after mid-stage trial data showed its lead drug reduced liver fat in patients with fatty liver disease, placing it ahead of larger rivals to tap into a potential market worth $30 billion.

31 May 2018

UPDATE 1-Madrigal Pharma's liver disease drug succeeds in study, shares soar

May 31 Madrigal Pharmaceuticals Inc said on Thursday its lead experimental drug achieved the main goal of reducing liver fat in patients with a type of liver disease in a mid-stage study, sending its shares surging 40 percent in premarket trading.

31 May 2018

Madrigal Pharma's liver disease drug succeeds in mid-stage trial

May 31 Madrigal Pharmaceuticals Inc said on Thursday a mid-stage trial testing its lead experimental treatment for a liver disease achieved the main goal of reducing liver fat.

31 May 2018

BRIEF-Madrigal Pharmaceuticals Reports Qtrly Loss Per Share Of $0.45

* MADRIGAL PHARMACEUTICALS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS AND REVIEWS KEY CLINICAL ACHIEVEMENTS

08 May 2018

BRIEF-Madrigal Pharmaceuticals Qtrly ‍Loss Per Share $0.67​

* MADRIGAL PHARMACEUTICALS REPORTS 2017 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS, REVIEWS KEY CORPORATE ACHIEVEMENTS AND PROVIDES CLINICAL UPDATE ON MGL-3196

13 Mar 2018

BRIEF-Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Heterozygous Familial Hypercholesterolemia

* MADRIGAL'S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)

08 Feb 2018

Earnings vs. Estimates